SIGA Technologies, Inc. is a commercial pharmaceutical company that concentrates on the health security and contagious disease markets in the United States. It offers TPOXX, an oral formulation antiviral medication as its primary product that treats human smallpox disease triggered by variola virus. The company has an alliance with Cipla Therapeutics to provide continuous innovation and availability of antibacterial drugs, primarily against biothreats.